ReviewApproaches to mitochondrially mediated cancer therapy
Introduction
Therapeutic approaches for highly resistant malignancies have, in general, centred around various adjuvant regimens involving surgical resection and cytotoxic radiotherapy and chemotherapy. Cytotoxic drug therapy has, for the most part, focussed upon agents which damage the nuclear DNA of tumour cells. Sadly, not only are some normal cells as well as the neoplastic cells likely to be destroyed by this approach but, significantly, cells which comprise some of most aggressive and resistant tumours are highly efficient at repairing DNA damage breaks. Among these highly resistant neoplasms are the intrinsic, primary brain tumours; the vast majority of which are thought to be derived from the glial cells or their progenitors and are generically classified as glioma. These are graded from I to IV in increasing degree of histologically defined malignancy, with grade I and II being deemed “benign”. Biologically however, any expansive, space-occupying lesion within the cranium must be considered as potentially life-threatening, particularly if it encroaches on eloquent or vital areas of the brain. Moreover, in adults such “grade II, benign” tumours almost invariably undergo progressive genetic change and subsequently represent as high grade malignant tumours which are then among the most difficult of tumours to treat effectively and carry a dismal prognosis. To further complicate the issue, the presence of the blood–brain barrier (B–BB) precludes access for all but lipid-soluble or low molecular weight therapeutic agents to the brain. The damaged vasculature of the major tumour mass does, however, to some extent permit modest entry of certain cytotoxic agents which do not constitutively cross the B–BB. This too is counteracted by the ability of tumour cells at the periphery of the lesion to diffusely infiltrate deep (often several centimetres) into the contiguous normal brain where they are protected by virtue of an intact B–BB. In addition, these invading neoplastic cells transiently arrest from the cell cycle during their migratory phase thereby rendering themselves refractory to radiotherapy [1], [2]. Yet another biological feature of the gliomas contributes to the difficulty posed in achieving a successful therapeutic response; their marked cellular heterogeneity. Not only may gliomas demonstrate a mixed cell population (e.g. astrocytes and oligodendrocytes within the same tumour), but there are known, through both histological and in vitro studies, to be numerous sub-populations present within the same phenotype (e.g. astrocytes). Here, tumour cells identified by the presence of the astrocyte marker, glial fibrillary acidic protein (GFAP) (Fig. 1a), show distinct “clones” displaying various morphologies (e.g. polygonal, fusiform, stellate, etc.) with differential expression of cell surface molecules, enzyme and growth factor synthesis and secretion. Indeed, these sub-groups of tumour cells can interact in a paracrine fashion to drive behaviour and malignant potential of the tumour [3], [4], [5].
This complex biology leaves currently used traditional chemotherapy approaches offering little long-term benefit for most malignant glioma patients and treatment is frequently associated with adverse side-effects that diminish the quality of life. Hence, new approaches are needed that can provide long-term management for malignant brain tumours, whilst permitting a decent quality of life [6]. In order to overcome the difficulties arising through the biological behaviour of primary brain tumours which severely hampers current therapeutic strategies it may be useful to consider the pre-requisites of an ideal agent to treat glioma:
- (a)
Passage across the B–BB.
- (b)
Low toxicity/side effects.
- (c)
Selective cytotoxicity—ability to destroy tumour but not normal brain cells.
- (d)
Trigger apoptosis through a mechanism not involving the nuclear DNA.
In consideration of the above features it has long been known that an alternative cellular pathway for chemotherapy exists—via the tumour cell mitochondria.
Section snippets
Mitochondria as cancer therapeutic targets
The rationale for targeting the mitochondria for therapeutic gain lies in the knowledge that this organelle plays a critical role in the regulation of energy metabolism, reactive oxygen species (ROS) production and apoptosis. It would appear difficult to target the energy metabolism of tumours as the host cells also rely upon the essential pathways for ATP supply. By identifying the most significant differences in the energy metabolism between tumour cells and normal brain cells, termed
Tricyclic drugs
In our laboratories we have investigated, in vitro, the efficacy of several alternative approaches to cancer therapy using the mitochondrial route. In particular, we and others, have shown that certain tricyclic antidepressants (Table 1) which have been used to competitively inhibit the serotonin and norepinephrine transporters for over 40 years, possess the potential to induce apoptosis in malignant glioma and neuroblastoma cells in vitro [18], [19], [20]. These lipophilic compounds, which
Cancer stem cells
The 120 kDa five-transmembrane cell surface protein, CD133 originally shown to be a haematopoietic stem cell marker [24], [25] has also been localised on normal human neural stem cells [26]. Subsequently, Singh et al. [27] demonstrated CD133 on “cancer stem cells” in brain tumour. Such CD133-positive, brain tumour stem cells can be magnetic immunobead and fluorescence activated cell sorted by use of dissociated cell suspensions and are also seen to express nestin but fail to express markers
Dexamethasone and valproic acid
In the UK most malignant glioma patients receive the steroid dexamethasone to reduce raised intracranial pressure. Current literature on the effects of dexamethasone on glioma cells is conflicting. Glucocorticoids have been reported to fulfil a functional role at the level of the mitochondrion [31] and have been shown to be neurotoxic, playing a role in neuronal cell death [32]. Dexamethasone also enhances necrotic cell death in glioma cells following serum deprivation [32]. In addition, it
Gangliosides
While drug-based approaches to induction of mitochondrially mediated apoptosis in cancer treatment carry potential there exist further possibilities to the same ends by modulating endogenous cellular processes using gene-based strategies. In this context, simple gangliosides may warrant further attention. Gangliosides are acidic glyco-sphingolipids that are present in high concentration, and are involved in, the early developmental stages of the brain when simple gangliosides such as GD3 are
Blood samples/clomipramine distribution
Blood plasma samples are taken at regular intervals, from clomipramine-treated anecdotal brain tumour patients and analysed using standard high-performance liquid chromatography (HPLC), to detect both clomipramine and its metabolite norclomipramine. A methodology is currently being developed for the measurement of dexamethasone via HPLC, and amitriptyline/nortriptyline can potentially be added to the range of tricyclics tested. The data taken from the analysis of blood plasma will be used to
Conclusions
The mitochondrial route to apoptosis in cancer treatment is, to a large extent, unexploited but there is, with some justification, an increased research activity in this area. In our own laboratories we have considered the potential of tricyclic drugs, hitherto used in control of obsessive compulsive disorder and clinical depression, in the treatment of malignant glioma. These drugs have only limited, and generally mild, side effects, cross the B–BB and are sequestered in the lung and brain in
Acknowledgements
We are indebted to the Samantha Dickson Brain Tumour Trust for supporting the tricyclic drug research presented and to Ali's Dream and Charlie's Challenge brain tumour charities for provision of ongoing funding for our ganglioside research programme also reported herein.
References (61)
- et al.
A2B5 surface ganglioside binding distinguishes between two GFAP-positive clones from a human glioma-derived line
Neurosci Lett
(1990) - et al.
Translocator protein (18 kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function
Trends Pharmacol Sci
(2006) - et al.
Peripheral benzodiazepine receptors and mitochondrial function
Neurochem Int
(2002) Targeting the Bcl-2 family in cancer therapy
Semin Oncol
(2006)- et al.
Peripheral benzodiazepine receptor ligands: mitochondrial transmembrane potential depolarization and apoptosis induction in rat C6 glioma cells
Biochem Pharmacol
(2004) - et al.
Chlorimipramine: a novel anticancer agent with a mitochondrial target
Biochem Biophys Res Commun
(2005) - et al.
A comparative study of in vivo inhibition of mitochondrial function in Saccharomyces cerevisiae by tricyclic and other centrally-acting drugs
Biochem Pharmacol
(1971) - et al.
AC133, a novel marker for human hematopoietic stem and progenitor cells
Blood
(1997) - et al.
A novel five-transmembrane hematopoietic stem cell antigen: isolation, characterization, and molecular cloning
Blood
(1997) - et al.
The dynamic localisation of the glucocorticoid receptor in rat C6 glioma cell mitochondria
Mol Cell Endocrinol
(2003)
Dexamethasone enhances serum deprivation-induced necrotic death of rat C6 glioma cells through activation of glucocorticoid receptors
Brain Res
Effect of growth factors on the in vitro growth and differentiation of early and late passage C6 glioma cells
Int J Dev Neurosci
Changes of mitochondrial respiration, mitochondrial content and cell size after induction of apoptosis in leukaemia cells
Biochim Biophys Acta
Dexamethasone pre-treatment interferes with apoptotic death in glioma cells
Neuroscience
Valproic acid modulates NCAM polysialylation and polysialyltransferase mRNA expression in human tumor cells
Int Immunopharmacol
Gangliosides in the human brain development and aging
Neurochem Int
Glycosphingolipid-dependent cross-talk between glycosynapses interfacing tumour cells with their host cells: essential basis to define tumour malignancy
FEBS Lett
Detection of medulloblastoma and astrocytoma-associated ganglioside GD3 in cerebrospinal fluid
Cancer Lett
Growth factors and gangliosides stimulate laminin production by glioma cells in vitro
Neurosci Lett
The effect of exogenous gangliosides on matrix metalloproteinase secretion by human glioma cells in vitro
Eur J Cancer
Vascular endothelial growth factor production is stimulated by gangliosides and TGF-ß isoforms in human glioma cells in vitro
Cancer Lett
Genes modulated by expression of GD3 synthase in Chinese hamster ovary cells. Evidence that the Tis21 gene is involved in the induction of GD3 9-O-acetylation
J Biol Chem
Lysosomal and cytosolic sialic acid 9-O-acetylesterase activities can be encoded by one gene via differential usage of a signal peptide-encoding exon at the N terminus
J Biol Chem
Tumour cell migration in the CNS
Brain Pathol
Migration and invasion in brain neoplasms
Curr Neurol Neurosci Rep
Glioma heterogeneity in vitro: the significance of growth factors and gangliosides
Neuropathol Appl Neurobiol
A human glioma cell line retains expression of GFAP and gangliosides recognised by A2B5 and LB1 antibodies, after prolonged passage
Neuropathol Appl Neurobiol
Malignant gliomas in 2005: where to GO from here?
JAMA
Energy metabolism in tumor cells
FEBS J
Mitochondrial medicine: pharmacological targeting of mitochondria in disease
Br J Pharmacol
Cited by (59)
Metal complexes targeting the Translocator Protein 18 kDa (TSPO)
2017, Coordination Chemistry ReviewsCitation Excerpt :A prolonged pore opening induces permeabilization of IMM and consequent osmotic swelling of the matrix with release of Cyt c and of the apoptosis inducing factor (AIF). These two pro-apoptotic proteins cause the activation of intracellular pathways responsible for the typical nuclear alterations of apoptotic cells [4,92,93]. Myxoma Poxvirus M11L is an anti-apoptotic protein, localized in the mitochondria, which can regulate the MPT pore complex by direct modulation of TSPO, thus preventing the loss of the mitochondrial inner membrane potential preluding to induction of apoptosis [94].
Biocatalytic conversion and detoxification of imipramine by the laccase-mediated system
2016, International Biodeterioration and BiodegradationCitation Excerpt :They can induce apoptosis in the cells of malignant glioma and neuroblastoma in vitro and zebra fish embryos. These effects result from restriction of the electron transport chain in mitochondria (Pilkington et al., 2008; Cordero et al., 2009; Parker et al., 2012). Also, TCAs are metabolized and conjugated by the liver, where some of them become pharmacologically active, and excreted by the kidneys (Kerr et al., 2001).
Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM)
2015, European Journal of Medicinal ChemistryMitochondrial dysfunction in gliomas
2013, Seminars in Pediatric NeurologyCitation Excerpt :In a small clinical trial of patients with glioblastoma, DCA was shown to decrease tumor growth and angiogenesis.110 Various tricyclic antidepressant drugs, such as clomipramine and amitriptyline, can enter the mt of tumor cells causing reduction of oxygen consumption, release of cytochrome c, and activation of the caspase cascade hence exerting their tumoricidal action through apoptosis in vitro; as such, these drugs can be used as potential anticancer agents aimed at targeting mt in gliomas.113,114 Clomipramine and its metabolite norclomipramine have been found to be potent inhibitors of cellular respiration in anaplastic astrocytoma cells in vitro thereby enhancing apoptotic cell death, an effect that is synergistically accentuated by dexamethasone.114
Antidepressants as Autophagy Modulators for Cancer Therapy
2023, Molecules